-
Something wrong with this record ?
NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours
M. Indrová, J. Símová, J. Bieblová, J. Bubeník, M. Reinis
Language English Country Greece
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
21109988
Knihovny.cz E-resources
- MeSH
- Antigens, Ly immunology MeSH
- Killer Cells, Natural immunology MeSH
- CD4-Positive T-Lymphocytes immunology MeSH
- CD8-Positive T-Lymphocytes immunology MeSH
- Enzyme-Linked Immunosorbent Assay MeSH
- Neoplasms, Experimental immunology MeSH
- NK Cell Lectin-Like Receptor Subfamily B immunology MeSH
- Human papillomavirus 16 MeSH
- Histocompatibility Antigens Class I immunology MeSH
- Mice, Inbred C57BL MeSH
- Mice MeSH
- Cancer Vaccines immunology MeSH
- Flow Cytometry MeSH
- Cell Separation MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Loss or downregulation of MHC class I molecules on tumour cells is a common mechanism by which tumours can escape T-cell mediated immune responses. In this study, we examined the role of different immune cell lineages in the development of immunity against tumours of the same aetiology but with different MHC class I expression. In vivo depletion of CD8+ cells, but not of CD4+ or NK1.1+ cells in the immunization period resulted in complete elimination of the protective effects of immunization with irradiated TC-1 cells (MHC class I-positive cell line) against the TC-1 tumour challenge. After immunization with irradiated TC-1/A9 or with MK16 tumour cells (MHC class I-deficient sublines) a remarkable dependence on the presence of NK1.1+ cells was observed, while the tumour growth inhibition after CD4+ or CD8+ depletion was not efficient. Cytotoxic activity induced by TC-1 cell immunization was significantly abrogated in the CD8+ and CD4+ but not NK1.1+ cell-depleted mice, as compared to the immunized only controls. After MK16 or TC-1/A9 cell immunization, NK1.1+ but not CD8+ and CD4+ cell-depleted mice displayed significant reduction of specific cytotoxicity. Mice immunized with TC-1 cells showed similar percentage of IFNγ producing cells in CD8+, CD4+ and NK1.1+ cell populations. On the other hand, the highest proportion of IFNγ producing cells after immunization with TC-1/A9 or MK16 cells was concentrated into the NK1.1-positive spleen cell population. Our data demonstrate that the development of immunity against MHC class I-deficient tumours is highly dependent on the activity NK1.1+ cell population.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12027262
- 003
- CZ-PrNML
- 005
- 20160324174317.0
- 007
- ta
- 008
- 120816s2011 gr f 000 0#eng||
- 009
- AR
- 035 __
- $a (PubMed)21109988
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Indrová, Marie $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic. marie.indrova@img.cas.cz
- 245 10
- $a NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours / $c M. Indrová, J. Símová, J. Bieblová, J. Bubeník, M. Reinis
- 520 9_
- $a Loss or downregulation of MHC class I molecules on tumour cells is a common mechanism by which tumours can escape T-cell mediated immune responses. In this study, we examined the role of different immune cell lineages in the development of immunity against tumours of the same aetiology but with different MHC class I expression. In vivo depletion of CD8+ cells, but not of CD4+ or NK1.1+ cells in the immunization period resulted in complete elimination of the protective effects of immunization with irradiated TC-1 cells (MHC class I-positive cell line) against the TC-1 tumour challenge. After immunization with irradiated TC-1/A9 or with MK16 tumour cells (MHC class I-deficient sublines) a remarkable dependence on the presence of NK1.1+ cells was observed, while the tumour growth inhibition after CD4+ or CD8+ depletion was not efficient. Cytotoxic activity induced by TC-1 cell immunization was significantly abrogated in the CD8+ and CD4+ but not NK1.1+ cell-depleted mice, as compared to the immunized only controls. After MK16 or TC-1/A9 cell immunization, NK1.1+ but not CD8+ and CD4+ cell-depleted mice displayed significant reduction of specific cytotoxicity. Mice immunized with TC-1 cells showed similar percentage of IFNγ producing cells in CD8+, CD4+ and NK1.1+ cell populations. On the other hand, the highest proportion of IFNγ producing cells after immunization with TC-1/A9 or MK16 cells was concentrated into the NK1.1-positive spleen cell population. Our data demonstrate that the development of immunity against MHC class I-deficient tumours is highly dependent on the activity NK1.1+ cell population.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antigeny Ly $x imunologie $7 D000950
- 650 _2
- $a CD4-pozitivní T-lymfocyty $x imunologie $7 D015496
- 650 _2
- $a CD8-pozitivní T-lymfocyty $x imunologie $7 D018414
- 650 _2
- $a protinádorové vakcíny $x imunologie $7 D019496
- 650 _2
- $a separace buněk $7 D002469
- 650 _2
- $a ELISA $7 D004797
- 650 _2
- $a průtoková cytometrie $7 D005434
- 650 _2
- $a MHC antigeny I. třídy $x imunologie $7 D015395
- 650 _2
- $a lidský papilomavirus 16 $7 D052162
- 650 _2
- $a buňky NK $x imunologie $7 D007694
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a lektinové receptory NK-buněk - podrodina B $x imunologie $7 D055651
- 650 _2
- $a experimentální nádory $x imunologie $7 D009374
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Šímová, Jana $7 xx0119399 $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, 142 20 Prague 4, Czech Republic
- 700 1_
- $a Bieblová, Jana $7 xx0127729 $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, 142 20 Prague 4, Czech Republic
- 700 1_
- $a Bubeník, Jan, $d 1940- $7 jk01020086 $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, 142 20 Prague 4, Czech Republic
- 700 1_
- $a Reiniš, Milan $7 xx0083033 $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, 142 20 Prague 4, Czech Republic
- 773 0_
- $w MED00179060 $t Oncology reports $x 1791-2431 $g Roč. 25, č. 1 (2011), s. 281-288
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21109988 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120816 $b ABA008
- 991 __
- $a 20160324174038 $b ABA008
- 999 __
- $a ok $b bmc $g 949304 $s 784608
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2011 $b 25 $c 1 $d 281-288 $i 1791-2431 $m Oncology reports $n Oncol Rep $x MED00179060
- LZP __
- $b NLK112 $a Pubmed-20120816/11/02